|
|
Article: Formulation Demonstrates Extended Release In Phase I Study.(diabetes drug candidate)(Brief Article)
- Article from:
- Diabetes Week
- Article date:
- September 10, 2001
CopyrightCOPYRIGHT 2001 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2001 SEP 10 - (NewsRx.com & NewsRx.net) --
Amylin Pharmaceuticals, Inc. and Alkermes, Inc. announced results from an initial safety study in healthy volunteers designed to investigate multiple long-acting release (LAR) formulations of Amylin's type 2 diabetes drug candidate AC2993 (synthetic exendin-4).
Sustained plasma concentrations of AC2993 were measured for greater than 30 days in all formulations tested. The study showed that AC2993 LAR was well tolerated. The AC2993 LAR formulations in this study are based on Alkermes, Inc.'s patented and proprietary Medisorb(R) injectable sustained-release drug delivery technology and are being developed by ...
Related newspaper, magazine, and journal articles:
|
|
Article: Amylin Pharmaceuticals Confirms Plan to Initiate ...
PR Newswire;
October 12, 2001 ;
700+ words
... ... FDA), Amylin Pharmaceuticals, Inc ... levels. Amylin Pharmaceuticals is engaged ... s lead drug candidate, SYMLIN ... s third drug candidate, AC3056 ... markets. Amylin Pharmaceuticals is based ...
|
|